Valeant Pharmaceuticals International Inc. executives strived to accentuate the positive during a second quarter earnings call Aug. 8 and investors didn't completely reject the argument, as the troubled company's stock closed the trading day up nearly 2%. However, to buy into the good news, one must accept Valeant's assurances that it can turn around a struggling dermatology franchise and that ahead-of-schedule debt reduction efforts will enable it to regain overall footing before a heavy debt crunch in 2020-21.
CEO Joseph Papa characterized Valeant's path to recovery from a mountain of debt, legal troubles and patent expirations as one in which stabilization occurred last year and recovery is underway this year and next. (Also see "Debt-laden Valeant Sells Its Assets, More Divestments Likely" - Scrip, 10 January, 2017
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?